Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Fibrinolytic Agents"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 124
Tytuł:
New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology.
Autorzy:
Bauer KA; Department of Medicine, Harvard Medical School, and Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.
Pokaż więcej
Źródło:
Chest [Chest] 2003 Dec; Vol. 124 (6 Suppl), pp. 364S-370S.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Factor Xa Inhibitors*
Fibrinolytic Agents/*therapeutic use
Polysaccharides/*therapeutic use
Postoperative Complications/*prevention & control
Venous Thrombosis/*prevention & control
Fibrinolytic Agents/chemistry ; Fibrinolytic Agents/metabolism ; Fondaparinux ; Humans ; Polysaccharides/chemistry ; Polysaccharides/metabolism ; Structure-Activity Relationship
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Snake venom, vampire bat saliva, or rt-PA: time matters.
Autorzy:
Kaste M; Department of Neurology, Helsinki University Central Hospital, University of Helsinki, 00029HUS Helsinki, Finland.
Pokaż więcej
Źródło:
Lancet (London, England) [Lancet] 2006 Nov 25; Vol. 368 (9550), pp. 1845-6.
Typ publikacji:
Comment; Journal Article
MeSH Terms:
Crotalid Venoms/*adverse effects
Fibrinolytic Agents/*administration & dosage
Plasminogen Activators/*administration & dosage
Stroke/*therapy
Animals ; Chiroptera ; Crotalid Venoms/therapeutic use ; Fibrinolytic Agents/therapeutic use ; Humans ; Plasminogen Activators/therapeutic use ; Randomized Controlled Trials as Topic ; Stroke/mortality ; Time Factors ; Tissue Plasminogen Activator/administration & dosage ; Tissue Plasminogen Activator/therapeutic use ; Treatment Failure
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Autorzy:
Warkentin TE; Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, General Site, 237 Barton St E, Hamilton, Ontario L8L 2X2, Canada. />Greinacher A
Pokaż więcej
Źródło:
Chest [Chest] 2004 Sep; Vol. 126 (3 Suppl), pp. 311S-337S.
Typ publikacji:
Comparative Study; Guideline; Journal Article; Practice Guideline; Review
MeSH Terms:
Fibrinolytic Agents/*adverse effects
Heparin/*adverse effects
Thrombocytopenia/*chemically induced
Dose-Response Relationship, Drug ; Drug Monitoring ; Evidence-Based Medicine ; Female ; Fibrinolytic Agents/administration & dosage ; Heparin/administration & dosage ; Heparin, Low-Molecular-Weight/administration & dosage ; Heparin, Low-Molecular-Weight/adverse effects ; Humans ; Platelet Count ; Pregnancy ; Randomized Controlled Trials as Topic ; Risk Assessment ; Thrombocytopenia/diagnosis ; Thrombocytopenia/prevention & control ; Vitamin K/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Autorzy:
Monagle P; Division of Laboratory Services, Royal Children's Hospital, Department of Paediatrics, University of Melbourne, Flemington Rd, Parkville, Melbourne, VIC, Australia 3052. />Chan A
Massicotte P
Chalmers E
Michelson AD
Pokaż więcej
Źródło:
Chest [Chest] 2004 Sep; Vol. 126 (3 Suppl), pp. 645S-687S.
Typ publikacji:
Guideline; Journal Article; Practice Guideline; Review
MeSH Terms:
Thrombolytic Therapy*
Fibrinolytic Agents/*therapeutic use
Thromboembolism/*drug therapy
Child ; Child, Preschool ; Contraindications ; Evidence-Based Medicine ; Fibrinolytic Agents/adverse effects ; Heparin/adverse effects ; Heparin/therapeutic use ; Heparin, Low-Molecular-Weight/adverse effects ; Heparin, Low-Molecular-Weight/therapeutic use ; Humans ; Infant ; Infant, Newborn ; International Normalized Ratio ; Randomized Controlled Trials as Topic ; Risk Assessment ; Secondary Prevention ; Thromboembolism/blood ; Thromboembolism/etiology ; Treatment Outcome ; Vitamin K/antagonists & inhibitors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Autorzy:
Popma JJ; Interventional Cardiology, Brigham and Women's Hospital, 75 Francis St, Tower 2-3A Room 311, Boston, MA 02115, USA. />Berger P
Ohman EM
Harrington RA
Grines C
Weitz JI
Pokaż więcej
Źródło:
Chest [Chest] 2004 Sep; Vol. 126 (3 Suppl), pp. 576S-599S.
Typ publikacji:
Comparative Study; Guideline; Journal Article; Practice Guideline; Review
MeSH Terms:
Angioplasty, Balloon, Coronary*
Stents*
Coronary Stenosis/*therapy
Fibrinolytic Agents/*therapeutic use
Hirudins/*analogs & derivatives
Ticlopidine/*analogs & derivatives
Abciximab ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Aspirin/adverse effects ; Aspirin/therapeutic use ; Clopidogrel ; Contraindications ; Coronary Restenosis/prevention & control ; Drug Therapy, Combination ; Evidence-Based Medicine ; Fibrinolytic Agents/adverse effects ; Heparin/adverse effects ; Heparin/therapeutic use ; Hirudins/adverse effects ; Humans ; Immunoglobulin Fab Fragments/adverse effects ; Immunoglobulin Fab Fragments/therapeutic use ; Peptide Fragments/adverse effects ; Peptide Fragments/therapeutic use ; Practice Guidelines as Topic ; Pyridines/adverse effects ; Pyridines/therapeutic use ; Recombinant Proteins/adverse effects ; Recombinant Proteins/therapeutic use ; Risk Assessment ; Ticlopidine/adverse effects ; Ticlopidine/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Antithrombotic therapy in valvular heart disease--native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Autorzy:
Salem DN; Tufts New England Medical Center, 750 Washington St, Boston, MA 02111, USA. />Stein PD
Al-Ahmad A
Bussey HI
Horstkotte D
Miller N
Pauker SG
Pokaż więcej
Źródło:
Chest [Chest] 2004 Sep; Vol. 126 (3 Suppl), pp. 457S-482S.
Typ publikacji:
Comparative Study; Guideline; Journal Article; Practice Guideline; Review
MeSH Terms:
Heart Valve Prosthesis*
Fibrinolytic Agents/*therapeutic use
Heart Valve Diseases/*drug therapy
Postoperative Complications/*drug therapy
Thromboembolism/*drug therapy
Aspirin/adverse effects ; Aspirin/therapeutic use ; Bioprosthesis ; Evidence-Based Medicine ; Fibrinolytic Agents/adverse effects ; Heart Valve Diseases/blood ; Heart Valve Diseases/complications ; Humans ; International Normalized Ratio ; Postoperative Complications/blood ; Prosthesis Design ; Randomized Controlled Trials as Topic ; Risk Assessment ; Secondary Prevention ; Thromboembolism/blood ; Vitamin K/antagonists & inhibitors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points.
Autorzy:
Turpie AG; Department of Medicine, Hamilton Health Sciences-General Hospital, 237 Barton St East, Hamilton, ON, L8L 2X2, Canada. />Bauer KA
Eriksson BI
Lassen MR
Pokaż więcej
Źródło:
Chest [Chest] 2004 Aug; Vol. 126 (2), pp. 501-8.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Orthopedic Procedures*
Enoxaparin/*therapeutic use
Fibrinolytic Agents/*therapeutic use
Polysaccharides/*therapeutic use
Venous Thrombosis/*prevention & control
Adolescent ; Double-Blind Method ; Endpoint Determination/methods ; Enoxaparin/administration & dosage ; Fibrinolytic Agents/administration & dosage ; Fondaparinux ; Humans ; Injections, Subcutaneous ; Polysaccharides/administration & dosage
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Impact of tirofiban on angiographic morphologic features of high-burden thrombus formation during direct percutaneous coronary intervention and short-term outcomes.
Autorzy:
Yip HK; Division of Cardiology, Chang Gung Memorial Hospital, Kaohsiung, 123 Ta Pei Road, Niao Sung Hsiang, Kaohsiung Hsien, 83301 Taiwan, Republic of China.
Wu CJ
Chang HW
Hsieh YK
Fang CY
Chen SM
Chen MC
Pokaż więcej
Źródło:
Chest [Chest] 2003 Sep; Vol. 124 (3), pp. 962-8.
Typ publikacji:
Clinical Trial; Comparative Study; Evaluation Study; Journal Article
MeSH Terms:
Angioplasty, Balloon, Coronary*
Coronary Angiography*
Stents*
Thrombolytic Therapy*
Coronary Circulation/*drug effects
Coronary Thrombosis/*drug therapy
Fibrinolytic Agents/*administration & dosage
Myocardial Infarction/*drug therapy
Tyrosine/*administration & dosage
Aged ; Coronary Thrombosis/diagnostic imaging ; Coronary Thrombosis/mortality ; Female ; Fibrinolytic Agents/adverse effects ; Humans ; Male ; Middle Aged ; Myocardial Infarction/diagnostic imaging ; Myocardial Infarction/mortality ; Platelet Glycoprotein GPIb-IX Complex/antagonists & inhibitors ; Premedication ; Recurrence ; Survival Rate ; Tirofiban ; Treatment Outcome ; Tyrosine/adverse effects ; Tyrosine/analogs & derivatives
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.
Autorzy:
Lassen MR; Department of Orthopaedics, University Hospital of Copenhagen Hillerød, DK-3400, Hillerød, Denmark. />Bauer KA
Eriksson BI
Turpie AG
Pokaż więcej
Corporate Authors:
European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee
Źródło:
Lancet (London, England) [Lancet] 2002 May 18; Vol. 359 (9319), pp. 1715-20.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Arthroplasty, Replacement, Hip*
Enoxaparin/*therapeutic use
Fibrinolytic Agents/*therapeutic use
Polysaccharides/*therapeutic use
Postoperative Complications/*prevention & control
Venous Thrombosis/*prevention & control
Adult ; Aged ; Aged, 80 and over ; Double-Blind Method ; Enoxaparin/administration & dosage ; Female ; Fibrinolytic Agents/administration & dosage ; Fondaparinux ; Hospital Mortality ; Humans ; Male ; Middle Aged ; Polysaccharides/administration & dosage ; Postoperative Care ; Preoperative Care
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.
Autorzy:
Turpie AG; Department of Medicine, General Division, Hamilton Health Sciences Corporation, Ontario, Hamilton, Canada. />Bauer KA
Eriksson BI
Lassen MR
Pokaż więcej
Corporate Authors:
PENTATHALON 2000 Study Steering Committee
Źródło:
Lancet (London, England) [Lancet] 2002 May 18; Vol. 359 (9319), pp. 1721-6.
Typ publikacji:
Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Arthroplasty, Replacement, Hip*
Enoxaparin/*therapeutic use
Fibrinolytic Agents/*therapeutic use
Polysaccharides/*therapeutic use
Postoperative Complications/*prevention & control
Venous Thrombosis/*prevention & control
Adult ; Aged ; Aged, 80 and over ; Double-Blind Method ; Enoxaparin/administration & dosage ; Female ; Fibrinolytic Agents/administration & dosage ; Fondaparinux ; Humans ; Male ; Middle Aged ; Polysaccharides/administration & dosage ; Postoperative Care ; Preoperative Care
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial.
Autorzy:
Bath PM; Centre for Vascular Research, University of Nottingham, Nottingham, UK. />Lindenstrom E
Boysen G
De Deyn P
Friis P
Leys D
Marttila R
Olsson J
O'Neill D
Orgogozo J
Ringelstein B
van der Sande J
Turpie AG
Pokaż więcej
Źródło:
Lancet (London, England) [Lancet] 2001 Sep 01; Vol. 358 (9283), pp. 702-10.
Typ publikacji:
Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Aspirin/*therapeutic use
Fibrinolytic Agents/*therapeutic use
Heparin, Low-Molecular-Weight/*therapeutic use
Stroke/*drug therapy
Aged ; Aged, 80 and over ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Fibrinolytic Agents/administration & dosage ; Heparin, Low-Molecular-Weight/administration & dosage ; Humans ; Male ; Stroke/mortality ; Tinzaparin ; Treatment Outcome ; Venous Thrombosis/prevention & control
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Too much, too little, or none at all: dealing with substandard and fake drugs.
Autorzy:
Wan Po AL; Centre for Evidence-Based Pharmacotherapy, Aston University, Aston Triangle, B4 7ET, Birmingham, UK.
Pokaż więcej
Źródło:
Lancet (London, England) [Lancet] 2001 Jun 16; Vol. 357 (9272), pp. 1904.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Comment
MeSH Terms:
Myocardial Reperfusion*
Thrombolytic Therapy*
Antibodies, Monoclonal/*administration & dosage
Drug and Narcotic Control/*legislation & jurisprudence
Fibrinolytic Agents/*administration & dosage
Immunoglobulin Fab Fragments/*administration & dosage
Myocardial Infarction/*drug therapy
Platelet Aggregation Inhibitors/*administration & dosage
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Recombinant Proteins/*administration & dosage
Tissue Plasminogen Activator/*administration & dosage
Abciximab ; Administration, Oral ; Aged ; Antibodies, Monoclonal/adverse effects ; Aspirin/administration & dosage ; Aspirin/adverse effects ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Fibrinolytic Agents/adverse effects ; Humans ; Immunoglobulin Fab Fragments/adverse effects ; Infusions, Intravenous ; Male ; Middle Aged ; Myocardial Infarction/mortality ; Platelet Aggregation Inhibitors/adverse effects ; Recombinant Proteins/adverse effects ; Survival Rate ; Tissue Plasminogen Activator/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
Autorzy:
Topol EJ; Desk F25, Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195, Cleveland, OH, USA.
Pokaż więcej
Corporate Authors:
GUSTO V Investigators
Źródło:
Lancet (London, England) [Lancet] 2001 Jun 16; Vol. 357 (9272), pp. 1905-14.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Myocardial Reperfusion*
Thrombolytic Therapy*
Antibodies, Monoclonal/*administration & dosage
Fibrinolytic Agents/*administration & dosage
Immunoglobulin Fab Fragments/*administration & dosage
Myocardial Infarction/*drug therapy
Platelet Aggregation Inhibitors/*administration & dosage
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Recombinant Proteins/*administration & dosage
Tissue Plasminogen Activator/*administration & dosage
Abciximab ; Administration, Oral ; Aged ; Antibodies, Monoclonal/adverse effects ; Aspirin/administration & dosage ; Aspirin/adverse effects ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Fibrinolytic Agents/adverse effects ; Humans ; Immunoglobulin Fab Fragments/adverse effects ; Infusions, Intravenous ; Male ; Middle Aged ; Myocardial Infarction/mortality ; Platelet Aggregation Inhibitors/adverse effects ; Recombinant Proteins/adverse effects ; Survival Rate ; Tissue Plasminogen Activator/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Medicolegal implications of the consensus conference.
Autorzy:
McIntyre K;
Pokaż więcej
Źródło:
Chest [Chest] 2001 Jan; Vol. 119 (1 Suppl), pp. 337S-343S.
Typ publikacji:
Consensus Development Conference; Journal Article; Review
MeSH Terms:
Fibrinolytic Agents*/therapeutic use
Quality of Health Care/*legislation & jurisprudence
Humans ; Informed Consent/legislation & jurisprudence ; Liability, Legal ; Practice Guidelines as Topic ; United States
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Intravenous thrombolysis in acute myocardial infarction.
Autorzy:
Ohman EM; Duke Clinical Research Institute, Durham, NC 27715, USA. />Harrington RA
Cannon CP
Agnelli G
Cairns JA
Kennedy JW
Pokaż więcej
Źródło:
Chest [Chest] 2001 Jan; Vol. 119 (1 Suppl), pp. 253S-277S.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Thrombolytic Therapy*
Fibrinolytic Agents/*therapeutic use
Myocardial Infarction/*drug therapy
Clinical Trials as Topic ; Fibrinolytic Agents/administration & dosage ; Humans ; Infusions, Intravenous ; Myocardial Reperfusion ; Thrombin/antagonists & inhibitors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Antithrombotic therapy in children.
Autorzy:
Monagle P
Michelson AD
Bovill E
Andrew M
Pokaż więcej
Źródło:
Chest [Chest] 2001 Jan; Vol. 119 (1 Suppl), pp. 344S-370S.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Fibrinolytic Agents*/therapeutic use
Administration, Oral ; Anticoagulants/therapeutic use ; Child ; Child, Preschool ; Heparin/therapeutic use ; Heparin, Low-Molecular-Weight/therapeutic use ; Humans ; Infant ; Infant, Newborn ; Platelet Aggregation Inhibitors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 124

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies